Compare Gilead Sciences, Inc. (GILD) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SYSCO Corporation — how do they compare? Gilead Sciences, Inc. trades at $136.22 (market cap $168.35B), while SYSCO Corporation trades at $85.01 (market cap $40.32B). The key difference: Gilead Sciences, Inc. is far larger — about 4.2× SYSCO Corporation's market cap, and SYSCO Corporation pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| GILD | SYY | |
|---|---|---|
Market Cap | $168.35B | $40.32B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $91.16 |
52-Week Low | $110.56 | $69.30 |
Enterprise Value | $191.42B | $53.50B |
Dividend Yield | 2.42% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
SYY trades at $85.24, up 1.63% with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings of $1.53 EPS, beating estimates, with revenue growth to $81.37B in 2025. Analyst consensus is bullish with 60% buy ratings and an $88.25 price target. Recent news highlights CEO discussions on CNBC and positive earnings coverage.
Outlook remains positive with steady revenue growth and efficiency initiatives driving margins. Risks include competitive pressures and macroeconomic uncertainty. The stock offers value with a P/S of 0.48 and dividend yield support, but high P/B of 15.12 warrants caution on valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
